India · Delayed Price · Currency is INR Lupin Company Description
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally.
The company operates in two segments: Pharmaceuticals and Others. It produces, develops, and markets various branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs).
The company also offers products in the therapeutic areas of cardiovascular, diabetology, asthama, pediatrics, central nervous system, gastro-intestinal, anti-infectives, anti-TB, cephalosporins, and nonsteroidal anti-inflammatory drug therapies.
In addition, it provides chronic therapies, and hospital-based products; products for diabetes and iron supplements for anemia, and a Budesonide-Formoterol combination for asthma.
Further, the company is involved in the provision of diagnostics services, and digital healthcare services; and neuro rehabilition business.
It operates through network consisting of labs and collection centers. The company has a strategic collaboration with TB Alliance to support the clinical development and commercialization of Telacebec for the treatment of tuberculosis, leprosy, and buruli ulcer.
The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001.
Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.
| Country | India |
| Founded | 1968 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 26,021 |
| CEO | Vinita Gupta |
Contact Details
Address: Kalpataru Inspire Mumbai, Maharashtra 400055 India | |
| Phone | 91 22 6640 2323 |
| Website | lupin.com |
Stock Details
| Ticker Symbol | LUPIN |
| Exchange | National Stock Exchange of India |
| Fiscal Year | April - March |
| Reporting Currency | INR |
| ISIN Number | INE326A01037 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Vinita D. Gupta | Chief Executive Officer and Executive Director |
| Ramesh Swaminathan | Executive Director, Global Chief Financial Officer, CRO and Head of API Plus SBU and IT |
| Christoph Funke | Chief Technical Operations Officer |
| Dr. Shahin Fesharaki | Chief Scientific Officer |
| Ravi Agrawal | Senior Vice President of Investor Relations and M&A |
| Rajalakshmi Azariah | Vice President and Global Head of Corporate Communications |
| Dr. Fabrice Egros M.B.A., Ph.D., Pharm.D. | President of Corporate Development |
| Yashwant S. Mahadik B.Com, MBA | President of Global Human Resources |
| Dr. Sofia Mumtaz | President of Legal and Compliance, Canada, ANZ, and NEA business |
| Dr. Cyrus Karkaria | President of Biotech Business |